modelA10BF03
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Voglibose | |
| ATC code: | A10BF03 | route: | oral |
| compartments: | 1 | |
| dosage: | 0.2 | mg |
| volume of distribution: | 5.7 | L |
| clearance: | 14.6 | L/h |
| other parameters in model implementation | ||
Voglibose is an oral alpha-glucosidase inhibitor used to improve postprandial blood glucose levels in patients with type 2 diabetes mellitus. It works by delaying the absorption of glucose from the intestines. Voglibose is approved and used in several Asian countries for diabetes management, but is not widely approved in the US or EU.
Pharmacokinetics
Pharmacokinetic parameters are reported for healthy adult volunteers after oral administration.
References
Kaku, K (2014). Efficacy of voglibose in type 2 diabetes. Expert opinion on pharmacotherapy 15(8) 1181–1190. DOI:10.1517/14656566.2014.918956 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24798092
Kim, HS, et al., & Shin, JG (2018). Pharmacodynamic effects of voglibose administered alone, administered with metformin, and administered with metformin in a fixed-dose combination in healthy Korean subjects . International journal of clinical pharmacology and therapeutics 56(11) 544–550. DOI:10.5414/CP203146 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30178742
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)